FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1573109478> ?p ?o ?g. }

• W1573109478 abstract "The hepatitis C virus (HCV) is a major global health problem with around 130-150 million individuals chronically infected and it is estimated that 2 millions are newly infected each year. The HCV infection is one of the major causes of liver disease and the infection is characterized by a slow and silent progression. Patients infected with HCV have an increased risk of developing fibrosis, cirrhosis and hepatocellular carcinoma. The effectiveness of new treatments has drastically improved during the last years and the cure rate is today around 90 %. However, several obstacles remain to be solved. Firstly, the treatment is associated with high costs. Secondly, there are still uncertainties whether patient groups such as children, pregnant women and treatment-experienced patients will be eligible for this treatment. Finally, the direct-acting antiviral (DAA) treatment does not protect against a re-infection. Also, only around 10 % of all chronic HCV carriers have access to treatment and the highest prevalence of HCV are seen in developing countries, which highlights the need of alternative less-expensive treatment strategies. In this thesis we developed and characterized new treatments strategies for HCV based on genetic vaccines and re-direction of T cells. We utilized the non-structural (NS) 3/4A and 5A proteins of HCV as vaccine antigens and as targets for re-directed T cells. Both the NS3/4A and NS5A proteins have essential functions in HCV life cycle. We generated an NS5A-based DNA vaccine and performed detailed characterization of its in vivo immunogenicity. We have previously developed a DNA vaccine based on NS3/4A that effectively primes immune responses in vivo. A codon optimized NS5A vaccine sequence was delivered intramuscularly in combination with in vivo electroporation for efficient uptake. The DNA vaccine activated NS5A-specific immune responses in both wild type and NS5A-transgenic (Tg) mice, with dysfunctional HCV-specific T cells. The vaccine primed responses were functional in vivo as evidenced by protection against in vivo tumor growth of NS5A-expressing cells. Furthermore, the vaccines were also used to develop NS3and NS5A-specific T cell receptors (TCRs). Both the NS3/4A and NS5A TCRs were able to inhibit HCV RNA replication in vitro albeit using different mechanisms, possibly related to differences in the T cell avidity. The NS3/4A and the NS5A vaccines activated distinct HCV-specific immune responses. The NS3/4A vaccine was dependent on IFNγ and CD8 T cells but not CD4 T cells, whereas the NS5A vaccine was dependent on both CD4 and CD8 T cells but not on IFNγ. This is consistent with high-avidity NS3-specific TCRs inducing polyfunctional T cells, as compared to the low-avidity NS5A TCRs inducing monofunctional T cells. Finally, we analyzed the possibility to improve the intrinsic immunogenicity of the NS5A vaccine. We have previously showed that the immunogenicity of a NS3/4A-based vaccine could be significantly increased by co-expression with IL-12 and the addition of heterologous sequences from hepatitis B virus core antigen (HBcAg). However, the immunogenicity of NS5A was enhanced by addition of HBcAg sequences, but not co-expression of IL-12. In conclusion, we have developed and evaluated new potential therapeutic interventions for the treatment of chronic HCV infection. Although the effective DAA treatment is available, it is clear that alternative treatment strategies are needed. These should be associated with lower costs and preferentially induce a post cure immunity that protect against re-infection. LIST OF PUBLICATIONS I. Fredrik Holmstrom, Anna Pasetto, Veronica Nahr, Anette Brass, Malte Kriegs, Eberhard Hildt, Kate E. Broderick, Margaret Chen, Gustaf Ahlen, and Lars Frelin. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8 T cell responses in wild-type and NS5A-transgenic mice. J Immunol. 2013 Feb 1;190(3):1113-24. II. Anna Pasetto, Lars Frelin, Soo Aleman, Fredrik Holmstrom, Anette Brass, Gustaf Ahlen, Erwin D. Brenndorfer, Volker Lohmann, Ralph Bartenschlager, Matti Sallberg, Antonio Bertoletti, and Margaret Chen. TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol. 2012 Nov 1;189(9):4510-9. III. Antony Chen, Gustaf Ahlen Erwin D. Brenndorfer, Anette Brass, Fredrik Holmstrom, Margaret Chen, Jonas Soderholm, David R. Milich, Lars Frelin, and Matti Sallberg. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J Immunol. 2011 May 1;186(9):5107-18. IV. Fredrik Holmstrom, Margaret Chen, Anangi Balasiddaiah, Gustaf Ahlen, and Lars Frelin. Functional differences in hepatitis C virus nonstructural (NS) 3/4Aand 5Aspecific T cell responses. Submitted manuscript. RELATED PUBLICATIONS I. Anne Fournillier, Lars Frelin, Emilie Jacquier, Gustaf Ahlen, Anette Brass, Estelle Gerossier, Fredrik Holmstrom, Kate E. Broderick, Niranjan Y. Sardesai, Jean-Yves Bonnefoy, Genevieve Inchauspe, and Matti Sallberg. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis. 2013 Sep;208(6):1008-19. II. Gustaf Ahlen, Fredrik Holmstrom, Anna Gibbs, Mats Alheim, and Lars Frelin. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther. 2014 Aug;21(8):739-50." @default.
• W1573109478 created "2016-06-24" @default.
• W1573109478 creator A5056255444 @default.
• W1573109478 date "2015-05-07" @default.
• W1573109478 modified "2023-09-26" @default.
• W1573109478 title "Development and evaluation of new therapeutic interventions for chronic hepatitis C virus infection" @default.
• W1573109478 cites W125481235 @default.
• W1573109478 cites W1490324405 @default.
• W1573109478 cites W1505139021 @default.
• W1573109478 cites W1507063812 @default.
• W1573109478 cites W1511803520 @default.
• W1573109478 cites W1530951444 @default.
• W1573109478 cites W1535549793 @default.
• W1573109478 cites W1538172952 @default.
• W1573109478 cites W1554085314 @default.
• W1573109478 cites W1556818178 @default.
• W1573109478 cites W1558813989 @default.
• W1573109478 cites W1594950156 @default.
• W1573109478 cites W1595507615 @default.
• W1573109478 cites W1622437624 @default.
• W1573109478 cites W1637454162 @default.
• W1573109478 cites W1673662691 @default.
• W1573109478 cites W1675164605 @default.
• W1573109478 cites W1866007085 @default.
• W1573109478 cites W1890880588 @default.
• W1573109478 cites W1914838920 @default.
• W1573109478 cites W1962838163 @default.
• W1573109478 cites W1963705735 @default.
• W1573109478 cites W1965190540 @default.
• W1573109478 cites W1965776393 @default.
• W1573109478 cites W1966049263 @default.
• W1573109478 cites W1966050666 @default.
• W1573109478 cites W1968376947 @default.
• W1573109478 cites W1969276730 @default.
• W1573109478 cites W1969720994 @default.
• W1573109478 cites W1971390768 @default.
• W1573109478 cites W1972821220 @default.
• W1573109478 cites W1973675889 @default.
• W1573109478 cites W1974750479 @default.
• W1573109478 cites W1974806147 @default.
• W1573109478 cites W1975564745 @default.
• W1573109478 cites W1978041599 @default.
• W1573109478 cites W1978670933 @default.
• W1573109478 cites W1979273971 @default.
• W1573109478 cites W1981136135 @default.
• W1573109478 cites W1982302584 @default.
• W1573109478 cites W1983090549 @default.
• W1573109478 cites W1985055250 @default.
• W1573109478 cites W1985680307 @default.
• W1573109478 cites W1986505810 @default.
• W1573109478 cites W1987119060 @default.
• W1573109478 cites W1987919467 @default.
• W1573109478 cites W1990058709 @default.
• W1573109478 cites W1990954596 @default.
• W1573109478 cites W1992603628 @default.
• W1573109478 cites W1992987492 @default.
• W1573109478 cites W1993274621 @default.
• W1573109478 cites W1994143142 @default.
• W1573109478 cites W1995388272 @default.
• W1573109478 cites W1999639656 @default.
• W1573109478 cites W2000806258 @default.
• W1573109478 cites W2000827554 @default.
• W1573109478 cites W2003579943 @default.
• W1573109478 cites W2004197577 @default.
• W1573109478 cites W2006309458 @default.
• W1573109478 cites W2006497369 @default.
• W1573109478 cites W2007198955 @default.
• W1573109478 cites W2007597873 @default.
• W1573109478 cites W2009551908 @default.
• W1573109478 cites W2010016853 @default.
• W1573109478 cites W2011500811 @default.
• W1573109478 cites W2012420380 @default.
• W1573109478 cites W2012666090 @default.
• W1573109478 cites W2012939150 @default.
• W1573109478 cites W2013092102 @default.
• W1573109478 cites W2013423087 @default.
• W1573109478 cites W2014388600 @default.
• W1573109478 cites W2014495927 @default.
• W1573109478 cites W2015199158 @default.
• W1573109478 cites W2015489330 @default.
• W1573109478 cites W2016081852 @default.
• W1573109478 cites W2016110802 @default.
• W1573109478 cites W2018744718 @default.
• W1573109478 cites W2019799886 @default.
• W1573109478 cites W2020007154 @default.
• W1573109478 cites W2020052970 @default.
• W1573109478 cites W2021199098 @default.
• W1573109478 cites W2021207134 @default.
• W1573109478 cites W2021668929 @default.
• W1573109478 cites W2022057836 @default.
• W1573109478 cites W2023545713 @default.
• W1573109478 cites W2024557230 @default.
• W1573109478 cites W2026151480 @default.
• W1573109478 cites W2026208522 @default.
• W1573109478 cites W2026613864 @default.
• W1573109478 cites W2027265343 @default.
• W1573109478 cites W2027545702 @default.
• W1573109478 cites W2027717772 @default.
• W1573109478 cites W2027828064 @default.
• W1573109478 cites W2028757382 @default.

• next